188 related articles for article (PubMed ID: 30326879)
21. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
24. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
25. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Martin-Broto J; Redondo A; Valverde C; Vaz MA; Mora J; Garcia Del Muro X; Gutierrez A; Tous C; Carnero A; Marcilla D; Carranza A; Sancho P; Martinez-Trufero J; Diaz-Beveridge R; Cruz J; Encinas V; Taron M; Moura DS; Luna P; Hindi N; Lopez-Pousa A
Ann Oncol; 2017 Dec; 28(12):2994-2999. PubMed ID: 29045512
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
28. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
[TBL] [Abstract][Full Text] [Related]
29. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
30. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Xiao X; Wang W; Wang Z
Paediatr Drugs; 2014 Dec; 16(6):503-12. PubMed ID: 25392156
[TBL] [Abstract][Full Text] [Related]
31. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
32. Toxic erythema of chemotherapy with periorbital and perioral involvement.
Tay EY; Lim YL
Singapore Med J; 2012 Nov; 53(11):e244-6. PubMed ID: 23192515
[TBL] [Abstract][Full Text] [Related]
33. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.
Rodriguez CO; Crabbs TA; Wilson DW; Cannan VA; Skorupski KA; Gordon N; Koshkina N; Kleinerman E; Anderson PM
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):197-206. PubMed ID: 19803732
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
36. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Hejna M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger WC; Marosi L; Schneeweiss B; Greul R; Scheithauer W
Cancer; 2000 Aug; 89(3):516-22. PubMed ID: 10931450
[TBL] [Abstract][Full Text] [Related]
37. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Yıldırım F; Baha A; Yurdakul AS; Ozturk C
Asian Pac J Cancer Prev; 2015; 16(17):7859-65. PubMed ID: 26625811
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
[TBL] [Abstract][Full Text] [Related]
40. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
